GrandResearchStore

Report Summary: Non-Invasive Prenatal Test (NIPT) are targeted at the detection of certain specific chromosomal aneuploidies from maternal blood sample in pregnant women at high risk for fetal aneuploidies. Currently, the prenatal testing market is experiencing a paradigm shift from conventional prenatal screening and diagnostic methods to non-invasive prenatal testing. This is mainly because of the advantages associated with NIPTs such as safety, accuracy, and no risk of miscarriage during the genetic screening test for common chromosomal abnormalities. NIPT is one of the most promising new areas of screening because it delivers highly actionable insights for empowering critical health decisions. The global non-invasive prenatal testing market is segmented on the basis of tests viz; Harmony, MaterniT21 PLUS, PrenaTest, Verifi, BambniTest, Panorama, InformaSeq, Non-Invasive Fetal Trisomy Test (NIFTY), VisibiliT, Veracity and IONA Test. NIPT has experienced ...